Maravai LifeSciences

MRVI

Market cap $1.07B

MRVI Hedge Fund Activity: Q1 2026 in Review

158 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2026, worth a combined $344M — down 18% from $421M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new MRVI positions and 24 closed out — a net gain of 4 holders — while 51 added to existing stakes and 52 trimmed.

The largest buyer was Braidwell, adding an estimated $6.4M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $18.1M.

• 158 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2026, down from 159 in Q4 2025.
• Funds reported $344M of Maravai LifeSciences stock for Q1 2026, down 18% quarter-over-quarter.
• 28 funds opened new Maravai LifeSciences positions in Q1 2026 and 24 closed out, a net change of +4 holders.
• The largest Maravai LifeSciences buyer in Q1 2026 was Braidwell, an estimated $6.4M added.
• The largest Maravai LifeSciences seller in Q1 2026 was T. Rowe Price Investment Management, an estimated $18.1M sold.

Based on aggregated 13F filings for Q1 2026.